Knowledge Synergies Between Small Innovators Can Accelerate Drug Development, Experts Speak Out
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - It may sound too idealistic but Israel Makov, Teva's former chief executive, believes the present drought of late-stage pipeline drugs can be filled if smaller companies doing research in "silos" share their specialized insights and form single entities to develop future drugs
You may also be interested in...
“Cluster Formation” Drives India’s Sun Pharma Chief To Invest In Smaller Pharma Units
Sun Pharma promoter makes early investments that could yield future strategic value
Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted
Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted